CorMedix Inc.

NasdaqGM:CRMD Stock Report

Market Cap: US$520.0m

CorMedix Management

Management criteria checks 3/4

CorMedix's CEO is Joe Todisco, appointed in May 2022, has a tenure of 2.58 years. total yearly compensation is $2.46M, comprised of 25.1% salary and 74.9% bonuses, including company stock and options. directly owns 0.3% of the company’s shares, worth $1.58M. The average tenure of the management team and the board of directors is 2.6 years and 2.8 years respectively.

Key information

Joe Todisco

Chief executive officer

US$2.5m

Total compensation

CEO salary percentage25.1%
CEO tenure2.6yrs
CEO ownership0.3%
Management average tenure2.6yrs
Board average tenure2.8yrs

Recent management updates

Here's Why CorMedix Inc.'s (NASDAQ:CRMD) CEO Compensation Is The Least Of Shareholders' Concerns

Nov 14
Here's Why CorMedix Inc.'s (NASDAQ:CRMD) CEO Compensation Is The Least Of Shareholders' Concerns

Recent updates

CorMedix Inc.'s (NASDAQ:CRMD) P/S Is On The Mark

Dec 13
CorMedix Inc.'s (NASDAQ:CRMD) P/S Is On The Mark

Here's Why CorMedix Inc.'s (NASDAQ:CRMD) CEO Compensation Is The Least Of Shareholders' Concerns

Nov 14
Here's Why CorMedix Inc.'s (NASDAQ:CRMD) CEO Compensation Is The Least Of Shareholders' Concerns

Analysts Just Made A Massive Upgrade To Their CorMedix Inc. (NASDAQ:CRMD) Forecasts

Nov 04
Analysts Just Made A Massive Upgrade To Their CorMedix Inc. (NASDAQ:CRMD) Forecasts

CorMedix 2.0: New Leadership, New Approval, New Focus

Oct 28

CorMedix: Delayed Approval, Low Cash, Good Prospects

Oct 19

We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely

Sep 30
We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely

We Think CorMedix (NASDAQ:CRMD) Can Afford To Drive Business Growth

Apr 06
We Think CorMedix (NASDAQ:CRMD) Can Afford To Drive Business Growth

We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely

Nov 02
We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

Jul 31
Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

CorMedix (NASDAQ:CRMD) Is In A Good Position To Deliver On Growth Plans

Feb 25
CorMedix (NASDAQ:CRMD) Is In A Good Position To Deliver On Growth Plans

FDA again rejects CorMedix's application for lead candidate DefenCath, shares sink ~60%

Aug 08

Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

Jul 16
Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely

Mar 01
We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

Sep 09
Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

CorMedix Inc.'s (NASDAQ:CRMD) Intrinsic Value Is Potentially 58% Above Its Share Price

Feb 11
CorMedix Inc.'s (NASDAQ:CRMD) Intrinsic Value Is Potentially 58% Above Its Share Price

We're Hopeful That CorMedix (NYSEMKT:CRMD) Will Use Its Cash Wisely

Jan 04
We're Hopeful That CorMedix (NYSEMKT:CRMD) Will Use Its Cash Wisely

CEO Compensation Analysis

How has Joe Todisco's remuneration changed compared to CorMedix's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$46m

Jun 30 2024n/an/a

-US$53m

Mar 31 2024n/an/a

-US$50m

Dec 31 2023US$2mUS$617k

-US$46m

Sep 30 2023n/an/a

-US$40m

Jun 30 2023n/an/a

-US$37m

Mar 31 2023n/an/a

-US$33m

Dec 31 2022US$3mUS$378k

-US$30m

Compensation vs Market: Joe's total compensation ($USD2.46M) is about average for companies of similar size in the US market ($USD2.22M).

Compensation vs Earnings: Joe's compensation has been consistent with company performance over the past year.

CEO

Joe Todisco (48 yo)

2.6yrs

Tenure

US$2,459,432

Compensation

Mr. Joseph Todisco, also known as Joe, MBA, serves as Chief Executive Officer of CorMedix Inc. since May 10, 2022. He has served as Director of CorMedix Inc. since March 18, 2022 and served as its Independ...

Leadership Team

NamePositionTenureCompensationOwnership
Joseph Todisco
CEO & Director2.6yrsUS$2.46m0.30%
$ 1.6m
Matthew David
Executive VP & CFO4.6yrsUS$1.03m0.017%
$ 89.4k
Erin Mistry
Executive VP & Chief Commercial Officer4.8yrsUS$1.26m0.024%
$ 124.4k
Elizabeth Masson-Hurlburt
Executive VP and Chief Clinical Strategy & Operations Officerless than a yearUS$844.81k0.013%
$ 67.7k
Kaufman Zelnick
Executive VPless than a yearno datano data
Donna Ucci
Senior VP & Head of Global Quality2.6yrsno datano data
Tushar Mukherjee
Senior VP & Head of Technical Operations1.9yrsno datano data

2.6yrs

Average Tenure

47yo

Average Age

Experienced Management: CRMD's management team is considered experienced (2.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Joseph Todisco
CEO & Director2.8yrsUS$2.46m0.30%
$ 1.6m
Myron Kaplan
Independent Chairman of the Board8.7yrsUS$191.96k0.30%
$ 1.6m
Alan Dunton
Independent Director5.8yrsUS$141.42k0.025%
$ 130.7k
Janet Dillione
Independent Director9.3yrsUS$147.42k0.088%
$ 458.3k
Steven Lefkowitz
Independent Director7.5yrsUS$162.42k0.13%
$ 664.1k
Gregory Duncan
Independent Director4.1yrsUS$141.42k0%
$ 0
Bruce Polsky
Member of Scientific Advisor Boardno datano datano data
Saravanan Balamuthusamy
Member of Scientific Advisory Board2.7yrsno datano data
Sara Bonnes
Member of Scientific Advisory Board2.7yrsno datano data
Aru Narendran
Member of Scientific Advisory Board2.7yrsno datano data
Hannah Newman
Member of Scientific Advisory Board2.7yrsno datano data
Jonathan Waitman
Member of Scientific Advisory Board2.7yrsno datano data

2.8yrs

Average Tenure

68yo

Average Age

Experienced Board: CRMD's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 03:20
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

CorMedix Inc. is covered by 18 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andrew D'SilvaB. Riley Securities, Inc.
Edward WhiteFBR Capital Markets & Co.
Morris AjzenmanGriffin Securities